Approval Briefs: Zohydro ER, Vyvanse For Binge Eating, Another Imbruvica Claim, Alcon Gains New Allergy Eye Drop
This article was originally published in The Pink Sheet Daily
Executive Summary
Reformulated opioid still doesn’t have abuse deterrence claim; Shire gains another indication for Vyvanse, this time in binge-eating; Imbruvica becomes the first drug approved for Waldenstrom’s macroglobulinemia; and, Alcon garners approval for once-daily eye drop.
You may also be interested in...
Dr Reddy’s Enters OTC Eyecare Space
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
With Pataday Extra Strength, Alcon Eyes Consumers Looking For OTC 24-Hour Eye Allergy Remedy
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Pataday Switch Approval Dilates Eye Drop Category As Alcon's OTC Sales Driver
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.